Ergoteles’s Mereo BioPharma MREO Stock Holding History

Ergoteles’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-132,784	Closed	-$99.6K	–	1578
2022 Q4	$99.6K	Buy	+132,784	New	+$109K	﹤0.01%	1222
2022 Q3	–	Sell	-529,300	Closed	-$593K	–	1824
2022 Q2	$593K	Buy	+529,300	New	+$410K	0.02%	766

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ergoteles's MREO Position: Q1 2023 in Review

Ergoteles sold out of Mereo BioPharma (MREO) in Q1 2023, closing a stake of 132,784 shares — an estimated $99.6K sold.

Ergoteles first reported a position in MREO in Q2 2022 and held it in 2 quarters. The position peaked at $593K in Q2 2022. 58 funds tracked by Wall St. Rank hold MREO as of Q1 2023.

Ergoteles reported no remaining Mereo BioPharma position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 132,784 Mereo BioPharma shares in Q1 2023, an estimated $99.6K.
Ergoteles first reported a position in Mereo BioPharma in Q2 2022 and held it in 2 quarters.
Ergoteles's Mereo BioPharma position peaked at $593K in Q2 2022.
58 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.